Given that the protein expression of PD-1 plus PD-L1 promotes the development and progression of cancers, inhibitors targeting the immune checkpoint of the PD-1/PD-L1 pathway may offer a potential therapeutic strategy for patients with DLBCL [10, 11]. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.